CAB-CTLA-4 (BA3071)
Advanced Solid Tumors
Phase 1/2Active (Status Uncertain)
Key Facts
About BioAtla
BioAtla's mission is to revolutionize cancer therapy by developing smarter, more targeted biologics with an improved therapeutic index. Its core achievement is the patented Conditionally Active Biologics (CAB) platform, which creates therapeutics activated specifically in the tumor microenvironment. The company's strategy leverages this platform to build a pipeline of CAB-based antibody-drug conjugates (ADCs) and T-cell engagers, targeting both novel and validated oncology antigens with potentially superior safety profiles. Despite promising technology, the company faces significant clinical and financial challenges as it advances its lead candidates through mid-stage trials.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |